https://www.pharmaradar360.com/article/astral-150tm-6eae77da267f4c7bPharma Surgeen2026-07-09T12:00:00.000ZAstral 150™https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharma Surgeen2026-07-09T11:22:09.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/science-in-motion-the-technologies-shaping-tomorrow-s-pharmaceutical-industry-e8c79cff4cdac921Pharma Surgeen2026-07-09T10:42:45.000ZScience in Motion: The Technologies Shaping Tomorrow's Pharmaceutical Industryhttps://www.pharmaradar360.com/article/30-2026-0da497c6889855bfPharma Surgeen2026-07-09T10:39:18.000ZΑΝΑΡΤΗΣΗ ΛΙΣΤΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΣΚΕΥΑΣΜΑΤΩΝ ΠΕΡΙΟΡΙΣΜΕΝΗΣ ΔΙΑΘΕΣΙΜΟΤΗΤΑΣ 30 ΙΟΥΝΙΟΥ 2026https://www.pharmaradar360.com/article/teva-teva-advances-tev-408-into-phase-2b-for-vitiligo-after-early-progress-544b715b3694bf23Pharma Surgeen2026-07-09T10:37:39.000ZTeva (TEVA) Advances TEV 408 Into Phase 2b For Vitiligo After Early Progresshttps://www.pharmaradar360.com/article/931-days-the-drug-approval-scandal-hiding-in-plain-sight-d7cbcfd237196033Pharma Surgeen2026-07-09T10:31:53.000Z931 days. The drug approval scandal hiding in plain sighthttps://www.pharmaradar360.com/article/biotech-s-digital-twin-dilemma-33b1623e57b488fdPharma Surgeen2026-07-09T10:30:28.000ZBiotech’s digital twin dilemmahttps://www.pharmaradar360.com/article/greenwood-capital-associates-llc-sells-142-082-shares-of-teva-pharmaceutical-ind-a2069f81be85211aPharma Surgeen2026-07-09T10:27:15.000ZGreenwood Capital Associates LLC Sells 142,082 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/pharmaceutical-packaging-summit-2026-3d9f9694a6622fe3Pharma Surgeen2026-07-09T10:25:31.000ZPharmaceutical Packaging Summit 2026https://www.pharmaradar360.com/article/evonik-invests-100-million-in-u-s-api-production-42c347c9fe6c8692Pharma Surgeen2026-07-09T10:13:39.000ZEvonik Invests $100 Million in U.S. API Productionhttps://www.pharmaradar360.com/article/class-2-medicines-recall-bristol-laboratories-limited-phenoxymethylpenicillin-25-01eaedddca8554b6Pharma Surgeen2026-07-09T10:07:16.000ZClass 2 Medicines Recall: Bristol Laboratories Limited, Phenoxymethylpenicillin 250 mg/5ml Sugar free Oral Solution BP, EL(26)A/33https://www.pharmaradar360.com/article/roy-jakobs-to-join-gsk-board-as-non-executive-director-cb0d5a54ca69147cPharma Surgeen2026-07-09T10:00:00.000ZRoy Jakobs to join GSK Board as Non-Executive Directorhttps://www.pharmaradar360.com/article/ukhsa-updates-heat-health-alerts-across-england-ed2386aedcea3cbcPharma Surgeen2026-07-09T09:52:04.000ZUKHSA updates heat health alerts across Englandhttps://www.pharmaradar360.com/article/the-biotech-bi-weekly-a-disease-modeling-research-grant-and-an-accelerator-progr-136f87ff3f13b024Pharma Surgeen2026-07-09T09:49:12.000ZThe biotech bi-weekly: a disease modeling research grant and an accelerator program for data-driven health start-upshttps://www.pharmaradar360.com/article/3bf4b717e6b46efbPharma Surgeen2026-07-09T09:47:56.000ZΕπαναδιατύπωση και Ανάρτηση Πρόσκλησης Εκδήλωσης Ενδιαφέροντος για Συνεργασία με Καθεστώς Α.Π.Υ. (Ορθή Επανάληψη)https://www.pharmaradar360.com/article/pharmaceutical-industry-adopts-disease-classification-for-obesity-to-align-with-375b1a876faf7cc0Pharma Surgeen2026-07-09T09:19:17.000ZPharmaceutical Industry Adopts Disease Classification for Obesity to Align with GLP-1 Medication Markethttps://www.pharmaradar360.com/article/dhsc-spending-over-25-000-12432027a49613e7Pharma Surgeen2026-07-09T08:58:43.000ZDHSC spending over £25,000https://www.pharmaradar360.com/article/dhsc-spending-over-25-000-march-2026-4ecb811897116b1ePharma Surgeen2026-07-09T08:58:12.000ZDHSC: spending over £25,000, March 2026https://www.pharmaradar360.com/article/dhsc-spending-over-25-000-april-2026-7a14df1ff5986eabPharma Surgeen2026-07-09T08:58:07.000ZDHSC: spending over £25,000, April 2026https://www.pharmaradar360.com/article/global-biotech-leaders-converge-at-uab-s-bac-2026-e11c4238554def98Pharma Surgeen2026-07-09T08:58:00.000ZGlobal Biotech Leaders Converge at UAB's BAC 2026https://www.pharmaradar360.com/article/does-tango-therapeutics-tngx-russell-growth-shift-reveal-its-true-biotech-identi-ddcebee6d0f6e18fPharma Surgeen2026-07-09T08:46:34.000ZDoes Tango Therapeutics' (TNGX) Russell Growth Shift Reveal Its True Biotech Identity to Institutions?https://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-tibet-rhodiola-pharmaceutical-holding-co-c-61effe861e03dfebPharma Surgeen2026-07-09T08:42:49.000ZEnterprise value to EBITDA forward of Tibet Rhodiola Pharmaceutical Holding Co. Class A – SSE:600211https://www.pharmaradar360.com/article/biotech-rally-rests-on-fundamentals-m-a-appetite-says-roty-s-faison-xlv-nysearca-4617a6dfa8480c43Pharma Surgeen2026-07-09T08:33:52.000ZBiotech rally rests on fundamentals, M&A appetite, says ROTY's Faison (XLV:NYSEARCA)https://www.pharmaradar360.com/article/the-quest-to-save-grace-and-clear-the-way-for-rare-disease-patients-everywhere-5c8d5ca3d7dce25fPharma Surgeen2026-07-09T08:31:50.000ZThe quest to save Grace — and clear the way for rare disease patients everywherehttps://www.pharmaradar360.com/article/ebola-and-marburg-haemorrhagic-fevers-outbreaks-and-case-locations-16b29cdb0bb31831Pharma Surgeen2026-07-09T08:30:15.000ZEbola and Marburg haemorrhagic fevers: outbreaks and case locationshttps://www.pharmaradar360.com/article/outbreaks-under-monitoring-in-2026-eb6ae222898106b1Pharma Surgeen2026-07-09T08:30:15.000ZOutbreaks under monitoring in 2026https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37Pharma Surgeen2026-07-09T08:30:14.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/mpox-clade-ib-and-clade-iib-outbreak-epidemiological-overview-99d096b3fc6f5884Pharma Surgeen2026-07-09T08:30:13.000ZMpox clade Ib and clade IIb outbreak: epidemiological overviewhttps://www.pharmaradar360.com/article/high-consequence-infectious-disease-country-specific-risk-11ed7e663ad962cePharma Surgeen2026-07-09T08:30:12.000ZHigh consequence infectious disease: country specific riskhttps://www.pharmaradar360.com/article/life-sciences-jobs-plan-7418017e22c905c6Pharma Surgeen2026-07-09T08:30:12.000ZLife Sciences Jobs Planhttps://www.pharmaradar360.com/article/virus-reference-department-vrd-user-manual-bad0eec46821b469Pharma Surgeen2026-07-09T08:30:11.000ZVirus Reference Department (VRD): user manualhttps://www.pharmaradar360.com/article/measles-historic-confirmed-cases-notifications-and-deaths-55822ba8c9246f07Pharma Surgeen2026-07-09T08:30:09.000ZMeasles: Historic confirmed cases, notifications and deathshttps://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report-2955927e098c6836Pharma Surgeen2026-07-09T08:30:05.000ZMRSA, MSSA, Gram-negative bacteraemia and CDI: quarterly reporthttps://www.pharmaradar360.com/article/ukhsa-evidence-reviews-8f54ff16e8d4cd78Pharma Surgeen2026-07-09T08:30:05.000ZUKHSA evidence reviewshttps://www.pharmaradar360.com/article/hand-hygiene-alternatives-to-soap-and-water-for-reducing-c-difficile-c51d2f2eaee482cdPharma Surgeen2026-07-09T08:30:03.000ZHand hygiene alternatives to soap and water for reducing C. difficilehttps://www.pharmaradar360.com/article/fda-plan-could-put-pharma-ads-out-of-reach-for-broadcasters-f66838d8b17a7d21Pharma Surgeen2026-07-09T08:30:00.000ZFDA Plan Could Put Pharma Ads Out Of Reach For Broadcasters.https://www.pharmaradar360.com/article/medipost-enrolls-and-treats-first-patient-in-u-s-phase-3-trial-of-cartistem-adva-cff97f3699db3787Pharma Surgeen2026-07-09T08:14:40.000ZMEDIPOST enrolls and treats first patient in U.S. Phase 3 trial of CARTISTEM, advancing U.S. commercializationhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-moleculin-biotech-inc-nasdaq-mbrx-47e569ad7fa0c6c9Pharma Surgeen2026-07-09T07:12:52.000ZEnterprise value to EBITDA forward of Moleculin Biotech, Inc. – NASDAQ:MBRXhttps://www.pharmaradar360.com/article/pharmaceutical-machine-learning-market-growth-to-accelerate-by-2035-amid-ai-driv-85facc4026702819Pharma Surgeen2026-07-09T07:06:10.000ZPharmaceutical Machine Learning Market Growth to Accelerate by 2035 Amid AI-Driven Bioprocessing Advances - News and Statisticshttps://www.pharmaradar360.com/article/setmelanotide-phase-3-trial-for-hypothalamic-obesity-published-in-nejm-50b9d1d1e1f5dfd1Pharma Surgeen2026-07-09T06:53:13.000ZSetmelanotide Phase 3 Trial for Hypothalamic Obesity Published in NEJMhttps://www.pharmaradar360.com/article/sunscreen-monograph-fda-adds-bemotrizinol-in-latest-update-4f568e05c16a4d70Pharma Surgeen2026-07-09T06:37:20.000ZSunscreen Monograph: FDA Adds Bemotrizinol in Latest Updatehttps://www.pharmaradar360.com/article/ionis-heart-drug-misses-key-goal-but-monotherapy-subgroup-hit-0cee8281df71d1dcPharma Surgeen2026-07-09T06:30:27.000ZIonis heart drug misses key goal, but monotherapy subgroup hithttps://www.pharmaradar360.com/article/novo-nordisk-launches-weekly-insulin-shot-awiqli-in-india-8e6e52751e41790ePharma Surgeen2026-07-09T06:23:00.000ZNovo Nordisk launches weekly insulin shot Awiqli in Indiahttps://www.pharmaradar360.com/article/accelerated-amortized-payment-of-convertible-bond-installment-c6b37637350b9310Pharma Surgeen2026-07-09T06:16:32.000ZAccelerated Amortized Payment of Convertible Bond Installmenthttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-jointown-pharmaceutical-group-co-ltd-class-7fd9ca5c8f554de8Pharma Surgeen2026-07-09T06:10:53.000ZEnterprise value to EBITDA forward of Jointown Pharmaceutical Group Co., Ltd. Class A – SSE:600998https://www.pharmaradar360.com/article/price-to-sales-forward-of-ningbo-menovo-pharmaceutical-co-ltd-class-a-sse-603538-2096f17cc25616f7Pharma Surgeen2026-07-09T06:05:03.000ZPrice to sales forward of Ningbo Menovo Pharmaceutical Co., Ltd. Class A – SSE:603538https://www.pharmaradar360.com/article/raman-spectroscopic-systems-market-growth-outlook-to-2035-pharmaceutical-and-sem-d90d1ee212bedba8Pharma Surgeen2026-07-09T05:51:10.000ZRaman Spectroscopic Systems Market Growth Outlook to 2035: Pharmaceutical and Semiconductor Verticals Lead Demand - News and Statisticshttps://www.pharmaradar360.com/article/roche-receives-ce-mark-for-blood-test-to-identify-tuberculosis-infection-8152791d9f530be5Pharma Surgeen2026-07-09T05:00:00.000ZRoche receives CE Mark for blood test to identify tuberculosis infectionhttps://www.pharmaradar360.com/article/mumbai-s-k-rustom-ice-cream-parlour-fda-suspends-licence-after-live-rats-and-hou-5afb08cabccd027ePharma Surgeen2026-07-09T04:21:09.000ZMumbai’s K Rustom Ice Cream Parlour: FDA Suspends Licence After Live Rats and Houseflies Foundhttps://www.pharmaradar360.com/article/invesco-pharmaceuticals-etf-or-first-trust-biotech-fund-which-drug-maker-focused-ba8a96ae30031bedPharma Surgeen2026-07-09T04:10:40.000ZInvesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?https://www.pharmaradar360.com/article/fda-names-produce-safety-director-b900f12e916fa811Pharma Surgeen2026-07-09T04:08:41.000ZFDA names produce safety directorhttps://www.pharmaradar360.com/article/yomiuri-towa-pharmaceutical-aims-to-boost-production-capacity-with-planned-acqui-d4a68b9133ca3f33Pharma Surgeen2026-07-09T04:02:00.000ZYomiuri: Towa Pharmaceutical Aims to Boost Production Capacity with Planned Acquisition of Tanabe Pharma Subsidiaryhttps://www.pharmaradar360.com/article/live-rats-houseflies-fda-suspends-license-of-mumbai-s-iconic-rustom-ice-cream-pa-393e4f488a7e119fPharma Surgeen2026-07-09T03:35:00.000ZLive rats, houseflies: FDA suspends license of Mumbai's iconic 'Rustom' ice cream parlour over food safety violationshttps://www.pharmaradar360.com/article/dea-s-own-pharmacologist-undercuts-marijuana-rescheduling-order-fde6c33089c4a055Pharma Surgeen2026-07-09T03:15:00.000ZDEA's Own Pharmacologist Undercuts Marijuana Rescheduling Orderhttps://www.pharmaradar360.com/article/sugar-land-supports-deliverit-group-s-new-pharmaceutical-facility-75da8bf9bd646dc6Pharma Surgeen2026-07-09T02:34:00.000ZSugar Land supports DeliverIt Group's new pharmaceutical facilityhttps://www.pharmaradar360.com/article/why-cmc-is-becoming-the-competitive-advantage-in-biotech-1b640514bae00d7aPharma Surgeen2026-07-09T02:01:09.000ZWhy CMC is Becoming the Competitive Advantage in Biotechhttps://www.pharmaradar360.com/article/biotech-m-a-surge-seen-as-going-beyond-blockbuster-deals-0b9f4765317dc0f8Pharma Surgeen2026-07-09T01:52:00.000ZBiotech M&A Surge Seen as Going Beyond Blockbuster Dealshttps://www.pharmaradar360.com/article/rhythm-pharmaceuticals-inc-announced-that-the-results-of-its-phase-3-transcend-c-cb8cdee824e66b7dPharma Surgeen2026-07-09T01:48:32.000ZRhythm Pharmaceuticals Inc. announced that the results of its Phase 3 Transcend clinical trial for acquired hypothalamic obesity have been published in the top international medical journal, The New England Journal of Medicine.https://www.pharmaradar360.com/article/2-fast-growing-pharmaceutical-stocks-to-buy-now-00a2f17e5257582dPharma Surgeen2026-07-09T01:05:00.000Z2 Fast-Growing Pharmaceutical Stocks to Buy Nowhttps://www.pharmaradar360.com/article/2-fast-growing-pharmaceutical-stocks-to-buy-now-f8a6583bd54ddb5cPharma Surgeen2026-07-09T00:25:00.000Z2 Fast-Growing Pharmaceutical Stocks to Buy Nowhttps://www.pharmaradar360.com/article/sarepta-announces-fda-acceptance-of-sndas-for-amondys-45-and-vyondys-53-7be94b2b54c2f9d1Pharma Surgeen2026-07-09T00:20:43.000ZSarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®https://www.pharmaradar360.com/article/kalohexis-confidentially-files-ipo-to-back-obesity-and-cachexia-portfolio-939d3455269f177bPharma Surgeen2026-07-09T00:01:24.000ZKalohexis confidentially files IPO to back obesity and cachexia portfoliohttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-4a54cabad5933109Pharma Surgeen2026-07-09T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/view-all-in-depth-f57711315ba4a48ePharma Surgeen2026-07-09T00:00:00.000ZView all in-depthhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-8e3dc87507ebe370Pharma Surgeen2026-07-09T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-5bf3abcc8552584dPharma Surgeen2026-07-09T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-877f45a04e48322cPharma Surgeen2026-07-09T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-af172079acca6dfaPharma Surgeen2026-07-09T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-467442fbd5737775Pharma Surgeen2026-07-09T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-d6ed57aed4cd7837Pharma Surgeen2026-07-09T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-6e5706adc7c20334Pharma Surgeen2026-07-09T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-7f18734f94e1cfa8Pharma Surgeen2026-07-09T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-88ebaf9542169375Pharma Surgeen2026-07-09T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-340b298d91bb063ePharma Surgeen2026-07-09T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-614cc78d0939d709Pharma Surgeen2026-07-09T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-e47b4e03b0e64cffPharma Surgeen2026-07-09T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-51be4aa57449444aPharma Surgeen2026-07-09T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-bbe86a0bc0d4af84Pharma Surgeen2026-07-09T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/secretarial-comments-on-the-consensus-based-entity-s-cbe-battelle-memorial-insti-47ce5fabe71a06d5Pharma Surgeen2026-07-09T00:00:00.000ZSecretarial Comments on the Consensus-Based Entity's (CBE) (Battelle Memorial Institute) 2025 Activities: Report to Congress and the Secretary of the Department of Health and Human Serviceshttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-d03cb9af82903cc0Pharma Surgeen2026-07-09T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/designation-of-phenethyl-halides-as-list-i-chemicals-87e71e02f52c9ce2Pharma Surgeen2026-07-09T00:00:00.000ZDesignation of Phenethyl Halides as List I Chemicalshttps://www.pharmaradar360.com/article/determination-that-tovalt-odt-zolpidem-tartrate-orally-disintegrating-tablets-5-b2fc1c38182caf6cPharma Surgeen2026-07-09T00:00:00.000ZDetermination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectivenesshttps://www.pharmaradar360.com/article/preliminary-application-of-antihypertensive-gene-detection-in-the-treatment-of-h-3acd1557d0c02aabPharma Surgeen2026-07-09T00:00:00.000ZPreliminary Application of Antihypertensive Gene Detection in the Treatment of Hypertension.https://www.pharmaradar360.com/article/prospective-pan-cancer-phosphoproteomics-at-clinical-scale-extends-therapeutic-o-e15b508c0d2a060dPharma Surgeen2026-07-09T00:00:00.000ZProspective pan-cancer phosphoproteomics at clinical scale extends therapeutic options in precision oncologyhttps://www.pharmaradar360.com/article/nonalcoholic-fatty-liver-disease-in-the-era-of-mafld-emerging-insights-into-mech-a4c595927eda82a5Pharma Surgeen2026-07-09T00:00:00.000ZNonalcoholic Fatty Liver Disease in the Era of MAFLD: Emerging Insights into Mechanisms, Diagnosis, and Personalized Management Global Burden and Economic Impacthttps://www.pharmaradar360.com/article/gene-therapy-in-glioblastoma-from-vector-engineering-to-immune-microenvironment-38b378a318f58adfPharma Surgeen2026-07-09T00:00:00.000ZGene Therapy in Glioblastoma: From Vector Engineering to Immune Microenvironment Reprogramminghttps://www.pharmaradar360.com/article/six-decades-of-kidney-transplantation-in-brazil-state-of-the-art-and-public-heal-435d88d46454e431Pharma Surgeen2026-07-09T00:00:00.000ZSix decades of kidney transplantation in Brazil: state of the art and public health implicationshttps://www.pharmaradar360.com/article/downregulation-of-il16-expression-induces-chemotherapeutic-drug-sensitivity-via-6cd7e3793206d162Pharma Surgeen2026-07-09T00:00:00.000ZDownregulation of IL16 Expression Induces Chemotherapeutic Drug Sensitivity via Increased Degradation of Mutant TP53 in Acute Myeloid Leukemia Cellshttps://www.pharmaradar360.com/article/figure-5-from-olamat-a-abu-owida-h-arabiat-a-ozel-p-2026-data-driven-prediction-e3030e2cb2974c1aPharma Surgeen2026-07-09T00:00:00.000ZFigure 5 from: Olamat A, Abu Owida H, Arabiat A, Ozel P (2026) Data-driven prediction of polydispersity in microfluidic liposome production for pharmaceutical formulation optimization. Pharmacia 73: e200497. https://doi.org/10.3897/pharmacia.73.e200497https://www.pharmaradar360.com/article/data-driven-stroke-prediction-leveraging-knn-for-early-detection-in-clinical-dat-1bd7030ab6713c9ePharma Surgeen2026-07-09T00:00:00.000ZData-Driven Stroke Prediction: Leveraging KNN for Early Detection in Clinical Datasetshttps://www.pharmaradar360.com/article/molecular-profiling-in-colon-cancer-integrating-research-with-clinical-practice-f017bdc6720cd8e3Pharma Surgeen2026-07-09T00:00:00.000ZMolecular Profiling in Colon Cancer: Integrating Research with Clinical Practicehttps://www.pharmaradar360.com/article/practical-nutritional-strategies-to-attenuate-physiological-stress-in-adolescent-5c82c4cc4b4fbde4Pharma Surgeen2026-07-09T00:00:00.000ZPractical Nutritional Strategies to Attenuate Physiological Stress in Adolescent Soccer Players: A Comparative Trial of CoQ10 and Taurinehttps://www.pharmaradar360.com/article/implants-in-adolescents-clinical-outcomes-after-growth-pattern-adapted-implant-p-f89f01759a978c95Pharma Surgeen2026-07-09T00:00:00.000ZImplants in Adolescents: Clinical Outcomes After Growth-Pattern-Adapted Implant Placementhttps://www.pharmaradar360.com/article/development-and-external-validation-of-an-explainable-machine-learning-model-for-3b643ad91196d5afPharma Surgeen2026-07-09T00:00:00.000ZDevelopment and External Validation of an Explainable Machine-Learning Model for Predicting Postoperative Pulmonary Complications in Older Adults Undergoing Degenerative Spine Surgeryhttps://www.pharmaradar360.com/article/clinical-utility-of-repeat-sacroiliac-joint-mri-in-patients-evaluated-for-axial-12c34f3b71fe5263Pharma Surgeen2026-07-09T00:00:00.000ZClinical Utility of Repeat Sacroiliac Joint MRI in Patients Evaluated for Axial Spondyloarthritis: A Real-World Cohort Studyhttps://www.pharmaradar360.com/article/wear-smile-a-multidisciplinary-telemedicine-based-smoking-cessation-program-assi-194c4f222d19ef8cPharma Surgeen2026-07-09T00:00:00.000ZWear-Smile: A Multidisciplinary Telemedicine-Based Smoking Cessation Program Assisted by Wearable Monitoring Devices for Persons Who Smoke—Protocol for a Randomized Controlled Trialhttps://www.pharmaradar360.com/article/optimizing-systematic-endoscopic-lymph-node-staging-in-non-small-cell-lung-cance-406ffbf992bb65f2Pharma Surgeen2026-07-09T00:00:00.000ZOptimizing Systematic Endoscopic Lymph Node Staging in Non-Small Cell Lung Cancer: Proposals for Integrating the 9th Edition N-Staging Classification into Clinical Practicehttps://www.pharmaradar360.com/article/gonadotropin-therapy-in-idiopathic-hypogonadal-non-obstructive-azoospermia-aphro-23c4cc007f82d772Pharma Surgeen2026-07-09T00:00:00.000ZGonadotropin therapy in idiopathic hypogonadal non-obstructive azoospermia (APHRODITE Groups 3–4): a multicenter randomized controlled trialhttps://www.pharmaradar360.com/article/pharmacology-education-embedded-within-longitudinal-community-patient-partnershi-502f0e326b37c966Pharma Surgeen2026-07-09T00:00:00.000ZPharmacology education embedded within longitudinal community patient partnerships: an interprofessional approach to medication safety and clinical applicationhttps://www.pharmaradar360.com/article/spontaneous-intracranial-hypotension-with-negative-brain-mri-findings-a-systemat-7d26a7908e95c60ePharma Surgeen2026-07-09T00:00:00.000ZSpontaneous intracranial hypotension with negative brain MRI findings: a systematic review of diagnostic strategies and clinical outcomeshttps://www.pharmaradar360.com/article/cell-and-extracellular-vesicle-therapies-for-aki-in-critical-care-clinical-trans-e3f589f0e315d3cePharma Surgeen2026-07-09T00:00:00.000ZCell and extracellular vesicle therapies for AKI in critical care: clinical translation, organ-support integration, and lessons learnedhttps://www.pharmaradar360.com/article/a-genetic-and-clinical-risk-factor-algorithm-to-aid-in-identifying-new-cases-of-8f9546a2197bad2bPharma Surgeen2026-07-09T00:00:00.000ZA genetic and clinical risk factor algorithm to aid in identifying new cases of chronic kidney disease from the general populationhttps://www.pharmaradar360.com/article/clinical-evaluation-and-management-of-pediatric-enuresis-a-study-at-bmu-c59a87a768900974Pharma Surgeen2026-07-09T00:00:00.000ZClinical Evaluation and Management of Pediatric Enuresis: A Study at BMUhttps://www.pharmaradar360.com/article/comparative-evaluation-of-laparoscopic-versus-open-ventral-incisional-hernia-rep-58305ec751a71be1Pharma Surgeen2026-07-09T00:00:00.000ZComparative Evaluation of Laparoscopic versus Open Ventral Incisional Hernia Repairhttps://www.pharmaradar360.com/article/incidence-patterns-severity-and-outcomes-of-acute-poisoning-cases-presenting-to-d116f2e3d7a5586dPharma Surgeen2026-07-09T00:00:00.000ZIncidence Patterns, Severity, And Outcomes of Acute Poisoning Cases Presenting to a Tertiary Care Emergency Departmenthttps://www.pharmaradar360.com/article/evidence-grounded-ai-for-longitudinal-clinical-management-in-musculoskeletal-car-ce56338bf857f1a0Pharma Surgeen2026-07-09T00:00:00.000ZEvidence-grounded AI for longitudinal clinical management in musculoskeletal carehttps://www.pharmaradar360.com/article/fecal-microbiota-transplantation-improves-clinical-symptoms-and-promotes-intesti-6963c455715ed6cfPharma Surgeen2026-07-09T00:00:00.000ZFecal Microbiota Transplantation Improves Clinical Symptoms and Promotes Intestinal Microecological Remodeling in Patients with Constipation Complicated by Anxiety: A Multi-omics Studyhttps://www.pharmaradar360.com/article/clinical-study-evaluating-the-perioperative-combination-of-duloxetine-and-pregab-7ca0a473940b4171Pharma Surgeen2026-07-09T00:00:00.000ZClinical study evaluating the perioperative combination of duloxetine and pregabalin to improve postoperative pain after mega-liposuction surgery under general anesthesia: a double-blind randomized clinical trialhttps://www.pharmaradar360.com/article/non-invasive-brain-stimulation-for-parkinson-s-disease-therapeutic-applications-55032b1b1ca66c3bPharma Surgeen2026-07-09T00:00:00.000ZNon-invasive Brain Stimulation for Parkinson’s Disease: Therapeutic Applications and Clinical Perspectiveshttps://www.pharmaradar360.com/article/association-between-denosumab-therapy-and-hypocalcemia-influence-of-concomitant-c251c430bbcf462fPharma Surgeen2026-07-09T00:00:00.000ZAssociation between Denosumab Therapy and Hypocalcemia: Influence of Concomitant Gastric Acid–Suppressive Agents and Other Clinical Parametershttps://www.pharmaradar360.com/article/understanding-the-small-print-a-5-year-review-of-readability-in-phase-i-trial-in-960e2329720cf92bPharma Surgeen2026-07-09T00:00:00.000ZUnderstanding the small print: a 5-year review of readability in phase I trial information leafletshttps://www.pharmaradar360.com/article/sustained-clinical-benefit-of-idursulfase-beta-in-mucopolysaccharidosis-ii-two-y-fa3f249bed1a3559Pharma Surgeen2026-07-09T00:00:00.000ZSustained clinical benefit of idursulfase beta in mucopolysaccharidosis II: two-year experience from a phase 3 extension study including patients switched from idursulfasehttps://www.pharmaradar360.com/article/effects-of-28-day-astaxanthin-supplementation-on-psychological-fatigue-and-bioch-09cdb7af5709af3cPharma Surgeen2026-07-09T00:00:00.000ZEffects of 28-day astaxanthin supplementation on psychological fatigue and biochemical markers in taekwondo athletes: a randomized controlled trialhttps://www.pharmaradar360.com/article/knowledge-improvement-on-premarital-hiv-counseling-with-pause-flipchart-versus-c-a5794c2bb94c3014Pharma Surgeen2026-07-09T00:00:00.000ZKnowledge improvement on premarital HIV counseling with PAUSE© flipchart versus conventional method: a cluster randomised controlled trialhttps://www.pharmaradar360.com/article/cofactor-functions-of-magnesium-in-complement-activation-and-antimicrobial-respo-803c5a7c4b2b32edPharma Surgeen2026-07-09T00:00:00.000ZCofactor functions of magnesium in complement activation and antimicrobial responseshttps://www.pharmaradar360.com/article/neonatal-genetic-sequencing-as-a-first-tier-option-a-real-world-clinical-impleme-c2fc85228b246432Pharma Surgeen2026-07-09T00:00:00.000ZNeonatal genetic sequencing as a first-tier option: a real-world clinical implementation study in Northern Chinahttps://www.pharmaradar360.com/article/agentic-ai-driven-closed-loop-analytical-systems-for-autonomous-pharmaceutical-m-29a015a46260f4e1Pharma Surgeen2026-07-09T00:00:00.000ZAgentic AI-driven closed-loop analytical systems for autonomous pharmaceutical method development and regulatory-aware analysishttps://www.pharmaradar360.com/article/extracellular-synthesis-of-cenps-and-znnps-using-thermophilic-anoxybacillus-flav-bd256bdd9072a73ePharma Surgeen2026-07-09T00:00:00.000ZExtracellular synthesis of CeNPs and ZnNPs using thermophilic Anoxybacillus flavithermus and Geobacillus stearothermophilus bacteria, and their biological activitieshttps://www.pharmaradar360.com/article/breast-conserving-therapy-versus-mastectomy-outcomes-across-different-clinical-c-56e5dafdf9ede7e0Pharma Surgeen2026-07-09T00:00:00.000ZBreast Conserving Therapy Versus Mastectomy: Outcomes Across Different Clinical Characteristicshttps://www.pharmaradar360.com/article/deciphering-b-cell-maturation-dynamics-in-hyper-igm-syndromes-f1dbbde19de7559dPharma Surgeen2026-07-09T00:00:00.000ZDeciphering B cell Maturation Dynamics in Hyper-IgM Syndromeshttps://www.pharmaradar360.com/article/domain-knowledge-guided-for-varicose-vein-classification-with-adaptive-clinical-3aebce2ccf15e826Pharma Surgeen2026-07-09T00:00:00.000ZDomain Knowledge Guided for Varicose Vein Classification with Adaptive Clinical Expertshttps://www.pharmaradar360.com/article/diagnostic-pitfalls-of-action-induced-tremor-a-case-report-of-benign-adult-famil-5ace3d739e6f8a3bPharma Surgeen2026-07-09T00:00:00.000ZDiagnostic Pitfalls of Action‐Induced Tremor: A Case Report of Benign Adult Familial Myoclonic Epilepsy Treated with Thalamic Lesioninghttps://www.pharmaradar360.com/article/mental-health-and-serious-drug-crime-a-case-control-study-bba53f44bf1e7a3bPharma Surgeen2026-07-09T00:00:00.000ZMental Health and Serious Drug Crime: A Case–Control Studyhttps://www.pharmaradar360.com/article/fda-plans-rules-to-rein-in-drug-ads-enable-proactive-release-of-crls-and-more-d37baf91a70cad39Pharma Surgeen2026-07-08T23:20:00.000ZFDA plans rules to rein in drug ads, enable proactive release of CRLs, and morehttps://www.pharmaradar360.com/article/invesco-pharmaceuticals-etf-or-first-trust-biotech-fund-which-drug-maker-focused-2430afb86acbb3f8Pharma Surgeen2026-07-08T23:04:00.000ZInvesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?https://www.pharmaradar360.com/article/life-sciences-sector-plan-one-year-on-9b7efa9f764f7323Pharma Surgeen2026-07-08T23:01:03.000ZLife Sciences Sector Plan: One Year Onhttps://www.pharmaradar360.com/article/life-sciences-sector-plan-084e6253e9ed0a39Pharma Surgeen2026-07-08T23:01:03.000ZLife Sciences Sector Planhttps://www.pharmaradar360.com/article/uk-life-sciences-attracts-3bn-investment-creating-jobs-and-faster-patient-treatm-69c4239af0302634Pharma Surgeen2026-07-08T23:01:00.000ZUK life sciences attracts £3bn investment, creating jobs and faster patient treatmentshttps://www.pharmaradar360.com/article/organ-on-a-chip-organoids-but-drug-testing-on-whole-organs-this-startup-is-betti-1720d0355f4972a3Pharma Surgeen2026-07-08T22:25:50.000ZOrgan-on-a-chip, Organoids, but Drug Testing on Whole Organs? This Startup is Betting On Ithttps://www.pharmaradar360.com/article/local-biotech-companies-may-get-option-to-report-finances-twice-a-year-bac12ecdb36261f8Pharma Surgeen2026-07-08T21:22:00.000ZLocal biotech companies may get option to report finances twice a yearhttps://www.pharmaradar360.com/article/rhythm-s-obesity-drug-data-lands-in-nejm-after-52-week-phase-3-trial-9d00cd3cfdd53adbPharma Surgeen2026-07-08T21:07:00.000ZRhythm’s obesity drug data lands in NEJM after 52-week Phase 3 trialhttps://www.pharmaradar360.com/article/alpha-1-antitrypsin-deficiency-drug-enters-ph3-trial-d10b7516dbf00a3ePharma Surgeen2026-07-08T20:44:23.000ZAlpha-1 Antitrypsin Deficiency Drug Enters Ph3 Trialhttps://www.pharmaradar360.com/article/fda-unveils-3-year-blueprint-to-expand-drug-development-for-minor-uses-and-minor-b56a5314f51a8930Pharma Surgeen2026-07-08T20:36:05.000ZFDA unveils 3-year blueprint to expand drug development for minor uses and minor specieshttps://www.pharmaradar360.com/article/new-york-pushes-to-become-major-us-biotech-hub-cebd85d9e27f0eaePharma Surgeen2026-07-08T20:33:53.000ZNew York pushes to become major US biotech hubhttps://www.pharmaradar360.com/article/amneal-and-adalvo-announce-fda-acceptance-for-review-of-two-u-s-andas-for-generi-b04164da9303bf4cPharma Surgeen2026-07-08T20:30:00.000ZAmneal and Adalvo Announce FDA Acceptance for Review of Two U.S. ANDAs for Generic Tirzepatide Autoinjectorhttps://www.pharmaradar360.com/article/180m-financing-supports-head-to-head-phase-3-ipf-drug-trial-64f16c77cbecb785Pharma Surgeen2026-07-08T20:20:45.000Z$180M financing supports head-to-head Phase 3 IPF drug trialhttps://www.pharmaradar360.com/article/alector-alec-sees-gsk-end-antibody-collaboration-while-repaying-10-4m-loan-48577b2f6951ed56Pharma Surgeen2026-07-08T20:06:23.000ZAlector (ALEC) sees GSK end antibody collaboration while repaying $10.4M loanhttps://www.pharmaradar360.com/article/tarsus-pays-75m-for-eye-drug-candidate-with-phase-3-ahead-2912c59964222548Pharma Surgeen2026-07-08T20:05:00.000ZTarsus pays $75M for eye drug candidate with Phase 3 aheadhttps://www.pharmaradar360.com/article/ai-as-reinvention-pharmexec-f080108223da0a0cPharma Surgeen2026-07-08T19:45:44.000ZAI as Reinvention | PharmExechttps://www.pharmaradar360.com/article/rsv-antiviral-zelicapavir-enters-late-stage-clinical-trials-db65899d03b76d21Pharma Surgeen2026-07-08T19:44:22.000ZRSV Antiviral Zelicapavir Enters Late-stage Clinical Trialshttps://www.pharmaradar360.com/article/biotech-merger-tests-ai-patient-stratification-against-ra-s-70-treatment-gap-865093ff89937872Pharma Surgeen2026-07-08T19:41:34.000ZBiotech Merger Tests AI Patient Stratification Against RA’s 70% Treatment Gaphttps://www.pharmaradar360.com/article/on-behalf-of-respighi-bidco-s-p-a-consob-approved-the-offer-document-5adb109bdf0f1a80Pharma Surgeen2026-07-08T19:13:20.000ZOn behalf of Respighi BidCo S.p.A – CONSOB approved the Offer Documenthttps://www.pharmaradar360.com/article/major-biotech-company-laying-off-103-more-employees-in-fifth-round-of-cuts-since-5ec6e105d5055c29Pharma Surgeen2026-07-08T18:19:00.000ZMajor biotech company laying off 103 more employees in fifth round of cuts since mid-2025https://www.pharmaradar360.com/article/fda-collects-ghee-honey-samples-during-inspection-a4baddaefd6523d2Pharma Surgeen2026-07-08T18:03:15.000ZFDA collects ghee, honey samples during inspectionhttps://www.pharmaradar360.com/article/scoop-to-soup-fda-freezes-licence-of-mumbai-s-iconic-ice-cream-outlet-after-rats-996f28e08938c082Pharma Surgeen2026-07-08T17:53:00.000ZScoop to soup: FDA freezes licence of Mumbai's iconic ice cream outlet after rats found on premiseshttps://www.pharmaradar360.com/article/dea-proposes-schedule-i-ban-for-the-first-gas-station-drug-tianeptine-2ddd241517ee489aPharma Surgeen2026-07-08T17:34:45.000ZDEA Proposes Schedule I Ban for the First “Gas Station Drug," Tianeptinehttps://www.pharmaradar360.com/article/errant-fda-policy-and-dramatic-rise-of-device-and-drug-recalls-news-article-ae29a2e4decd1f3dPharma Surgeen2026-07-08T17:12:56.000ZErrant FDA Policy and Dramatic Rise of Device and Drug Recalls : News Articlehttps://www.pharmaradar360.com/article/powering-scientific-discovery-byokg-and-graphrag-for-intelligent-pharmaceutical-155b1e0c49a833f7Pharma Surgeen2026-07-08T16:57:12.000ZPowering scientific discovery: BYOKG and GraphRAG for intelligent pharmaceutical researchhttps://www.pharmaradar360.com/article/amgen-ecovation-how-amgen-builds-sustainability-into-biotech-52bd0d751ed179dcPharma Surgeen2026-07-08T16:40:16.000ZAmgen Ecovation®: How Amgen Builds Sustainability Into Biotechhttps://www.pharmaradar360.com/article/pharmaceutical-company-to-build-rare-manufacturing-facility-in-sugar-land-02ca74d9c23c55ccPharma Surgeen2026-07-08T16:24:00.000ZPharmaceutical company to build rare manufacturing facility in Sugar Landhttps://www.pharmaradar360.com/article/campylobacter-infection-annual-data-02c1dd6f758d5376Pharma Surgeen2026-07-08T16:20:55.000ZCampylobacter infection: annual datahttps://www.pharmaradar360.com/article/why-the-government-must-urgently-raise-the-nice-cost-effectiveness-threshold-1b734b641caf26ebPharma Surgeen2026-07-08T16:16:12.000ZWhy the government must urgently raise the NICE cost-effectiveness thresholdhttps://www.pharmaradar360.com/article/understanding-nhs-medicines-spending-in-england-8db3f6e3ab405423Pharma Surgeen2026-07-08T16:12:08.000ZUnderstanding NHS medicines spending in Englandhttps://www.pharmaradar360.com/article/abpi-response-to-life-sciences-competitiveness-indicators-8b0806f016033b51Pharma Surgeen2026-07-08T16:10:13.000ZABPI response to Life Sciences Competitiveness Indicatorshttps://www.pharmaradar360.com/article/astrazeneca-gsk-intensify-china-ties-with-sino-biopharm-deals-d60ddd5088aff017Pharma Surgeen2026-07-08T16:05:55.000ZAstraZeneca, GSK intensify China ties with Sino Biopharm dealshttps://www.pharmaradar360.com/article/health-protection-in-children-and-young-people-s-settings-including-education-cca215b8fd3fb49bPharma Surgeen2026-07-08T15:46:52.000ZHealth protection in children and young people's settings, including educationhttps://www.pharmaradar360.com/article/fda-suspends-licence-of-iconic-mumbai-ice-cream-outlet-k-rustom-over-food-safety-c7e9e6ac4edf5e59Pharma Surgeen2026-07-08T15:46:14.000ZFDA suspends licence of iconic Mumbai ice cream outlet K Rustom over food safety violationshttps://www.pharmaradar360.com/article/keenova-therapeutics-reports-positive-phase-3-xiaflex-data-f011a43b4089683cPharma Surgeen2026-07-08T15:11:00.000ZKeenova Therapeutics Reports Positive Phase 3 XIAFLEX Datahttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-08T15:10:06.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/sana-biotech-heads-to-easd-with-diabetes-cell-therapy-update-cf157e00e3c07a2aPharma Surgeen2026-07-08T15:01:48.000ZSana Biotech heads to EASD with diabetes cell therapy updatehttps://www.pharmaradar360.com/article/is-regeneron-pharmaceuticals-inc-regn-stock-still-a-biotech-leader-after-analyst-1857d66e693af959Pharma Surgeen2026-07-08T14:54:20.000ZIs Regeneron Pharmaceuticals, Inc. (REGN) Stock Still a Biotech Leader After Analyst Price Target Cut?https://www.pharmaradar360.com/article/community-pharmacy-could-help-ease-2-7bn-delayed-discharge-bill-f757f1f3e5116a24Pharma Surgeen2026-07-08T14:49:17.000ZCommunity pharmacy could help ease £2.7bn delayed discharge billhttps://www.pharmaradar360.com/article/europe-will-accelerate-its-review-of-revmed-s-drug-8701ab0d88ea3d66Pharma Surgeen2026-07-08T14:26:47.000ZEurope will accelerate its review of RevMed’s drughttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-08T14:21:44.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/novo-nordisk-signs-pact-with-vivani-for-long-lasting-semaglutide-implant-27a367a14db8bfc5Pharma Surgeen2026-07-08T14:15:58.000ZNovo Nordisk signs pact with Vivani for long-lasting semaglutide implanthttps://www.pharmaradar360.com/article/fda-cracks-down-on-illegal-ketamine-sellers-amid-nearing-psychedelic-revolution-8d19aabfb7894451Pharma Surgeen2026-07-08T14:15:58.000ZFDA cracks down on illegal ketamine sellers amid nearing ‘psychedelic revolution’https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-20-report-data-to-week-19-dat-eb9151086d6e9097Pharma Surgeen2026-07-08T14:11:15.000ZNational flu and COVID-19 surveillance report, week 20 report: data to week 19 (data up to 16 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-19-report-data-to-week-18-dat-e6e641100e95a23bPharma Surgeen2026-07-08T14:10:50.000ZNational flu and COVID-19 surveillance report, week 19 report: data to week 18 (data up to 9 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-18-report-data-to-week-17-dat-a1383c1237b314a4Pharma Surgeen2026-07-08T14:10:26.000ZNational flu and COVID-19 surveillance report, week 18 report: data to week 17 (data up to 2 May 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-17-report-data-to-week-16-dat-f7b834d10f61e6d1Pharma Surgeen2026-07-08T14:09:59.000ZNational flu and COVID-19 surveillance report, week 17 report: data to week 16 (data up to 25 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-16-report-data-to-week-15-dat-42aecb93111f49c0Pharma Surgeen2026-07-08T14:09:32.000ZNational flu and COVID-19 surveillance report, week 16 report: data to week 15 (data up to 18 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-15-report-data-to-week-14-dat-373827dc7348e461Pharma Surgeen2026-07-08T14:09:00.000ZNational flu and COVID-19 surveillance report, week 15 report: data to week 14 (data up to 11 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-14-report-data-to-week-13-dat-cb071690108f0c13Pharma Surgeen2026-07-08T14:08:32.000ZNational flu and COVID-19 surveillance report, week 14 report: data to week 13 (data up to 4 April 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-13-report-data-to-week-12-dat-f34f7e46e0cbc218Pharma Surgeen2026-07-08T14:07:57.000ZNational flu and COVID-19 surveillance report, week 13 report: data to week 12 (data up to 28 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-12-report-data-to-week-11-dat-2248d925c1565b0bPharma Surgeen2026-07-08T14:07:25.000ZNational flu and COVID-19 surveillance report, week 12 report: data to week 11 (data up to 21 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-11-report-data-to-week-10-dat-d006ba9728d2f42bPharma Surgeen2026-07-08T14:06:52.000ZNational flu and COVID-19 surveillance report, week 11 report: data to week 10 (data up to 14 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-10-report-data-to-week-9-data-65ae1db376478d6cPharma Surgeen2026-07-08T14:06:27.000ZNational flu and COVID-19 surveillance report, week 10 report: data to week 9 (data up to 7 March 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-9-report-data-to-week-8-data-da8467c5e0181f25Pharma Surgeen2026-07-08T14:06:02.000ZNational flu and COVID-19 surveillance report, week 9 report: data to week 8 (data up to 28 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-8-report-data-to-week-7-data-9c8304d98790e067Pharma Surgeen2026-07-08T14:05:06.000ZNational flu and COVID-19 surveillance report, week 8 report: data to week 7 (data up to 21 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-7-report-data-to-week-6-data-3361a06bc06c6f4bPharma Surgeen2026-07-08T14:04:35.000ZNational flu and COVID-19 surveillance report, week 7 report: data to week 6 (data up to 14 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-6-report-data-to-week-5-data-440549a3da1d18e2Pharma Surgeen2026-07-08T14:04:07.000ZNational flu and COVID-19 surveillance report, week 6 report: data to week 5 (data up to 7 February 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-5-report-data-to-week-4-data-2670f011693f7bf0Pharma Surgeen2026-07-08T14:03:41.000ZNational flu and COVID-19 surveillance report, week 5 report: data to week 4 (data up to 31 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-4-report-data-to-week-3-data-a451d64aae8e2df2Pharma Surgeen2026-07-08T14:02:59.000ZNational flu and COVID-19 surveillance report, week 4 report: data to week 3 (data up to 24 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-3-report-data-to-week-2-data-f473d78c142df7fePharma Surgeen2026-07-08T14:02:32.000ZNational flu and COVID-19 surveillance report, week 3 report: data to week 2 (data up to 17 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-2-report-data-to-week-1-data-dd4d02f23e4aa08fPharma Surgeen2026-07-08T13:50:13.000ZNational flu and COVID-19 surveillance report, week 2 report: data to week 1 (data up to 10 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-1-report-data-to-week-53-data-72725bd97f2ed752Pharma Surgeen2026-07-08T13:49:36.000ZNational flu and COVID-19 surveillance report, week 1 report: data to week 53 (data up to 3 January 2027)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-51-report-data-to-week-50-dat-8fbe46553359f327Pharma Surgeen2026-07-08T13:48:59.000ZNational flu and COVID-19 surveillance report, week 51 report: data to week 50 (data up to 13 December 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-50-report-data-to-week-49-dat-96d62d373813c277Pharma Surgeen2026-07-08T13:48:33.000ZNational flu and COVID-19 surveillance report, week 50 report: data to week 49 (data up to 6 December 2026)https://www.pharmaradar360.com/article/satellos-intriguing-duchenne-data-raise-hopes-ahead-of-key-readout-c1cfaf80d711d5e7Pharma Surgeen2026-07-08T13:48:20.000ZSatellos’ ‘intriguing’ Duchenne data raise hopes ahead of key readouthttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-49-report-data-to-week-48-dat-732f8ad5e6e1472ePharma Surgeen2026-07-08T13:47:57.000ZNational flu and COVID-19 surveillance report, week 49 report: data to week 48 (data up to 29 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-48-report-data-to-week-47-dat-35618b8fe7abe17cPharma Surgeen2026-07-08T13:47:25.000ZNational flu and COVID-19 surveillance report, week 48 report: data to week 47 (data up to 22 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-47-report-data-to-week-46-dat-60cf61f2680e7827Pharma Surgeen2026-07-08T13:46:47.000ZNational flu and COVID-19 surveillance report, week 47 report: data to week 46 (data up to 15 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-46-report-data-to-week-45-dat-19d5c7cb431f423bPharma Surgeen2026-07-08T13:46:05.000ZNational flu and COVID-19 surveillance report, week 46 report: data to week 45 (data up to 8 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-45-report-data-to-week-44-dat-2a309b29b8631ad3Pharma Surgeen2026-07-08T13:42:11.000ZNational flu and COVID-19 surveillance report, week 45 report: data to week 44 (data up to 1 November 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-44-report-data-to-week-43-dat-34f205820f4e2f50Pharma Surgeen2026-07-08T13:41:23.000ZNational flu and COVID-19 surveillance report, week 44 report: data to week 43 (data up to 25 October 2026)https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-43-report-data-to-week-42-dat-99cbb355a95c8f35Pharma Surgeen2026-07-08T13:39:15.000ZNational flu and COVID-19 surveillance report, week 43 report: data to week 42 (data up to 18 October 2026)https://www.pharmaradar360.com/article/why-is-satellos-bioscience-trading-higher-today-satellos-bioscience-nasdaq-msle-1f7c5626972b3fa4Pharma Surgeen2026-07-08T13:34:20.000ZWhy Is Satellos Bioscience Trading Higher Today? - Satellos Bioscience (NASDAQ:MSLE)https://www.pharmaradar360.com/article/deanna-horner-s-five-year-outlook-for-direct-to-patient-care-1176711a56fa57f9Pharma Surgeen2026-07-08T13:32:58.000ZDeanna Horner's Five-Year Outlook for Direct-to-Patient Carehttps://www.pharmaradar360.com/article/biotech-growth-trust-the-biotech-rebound-powered-by-innovation-valuations-and-ph-dab12e41f9069d0aPharma Surgeen2026-07-08T13:22:30.000ZBiotech Growth Trust: The biotech rebound powered by innovation, valuations and pharma’s patent cliffhttps://www.pharmaradar360.com/article/looking-after-children-and-those-in-early-years-settings-before-and-during-hot-w-5472a0a61f54d041Pharma Surgeen2026-07-08T13:10:03.000ZLooking after children and those in early years settings before and during hot weather: teachers and other educational professionalshttps://www.pharmaradar360.com/article/deliverit-to-build-12m-pharmaceutical-manufacturing-facility-in-sugar-land-5fe5bd8c806a239fPharma Surgeen2026-07-08T13:00:00.000ZDeliverIt to build $12M pharmaceutical manufacturing facility in Sugar Landhttps://www.pharmaradar360.com/article/erexon-intense-blue-vigueur-capsule-b-7704a3f903cb8982Pharma Surgeen2026-07-08T12:58:29.000ZEREXON INTENSE BLUE και VIGUEUR CAPSULE (ΣΙΛΔΕΝΑΦΙΛΗ, ΤΑΔΑΛΑΦΙΛΗ, BΑΡΔΕΝΑΦΙΛΗ)https://www.pharmaradar360.com/article/takeda-pharmaceutical-completes-share-issuance-disposal-under-incentive-plan-30e64b821030c095Pharma Surgeen2026-07-08T12:50:08.000ZTakeda Pharmaceutical Completes Share Issuance, Disposal Under Incentive Planhttps://www.pharmaradar360.com/article/sanner-group-50fa5b88896ed69dPharma Surgeen2026-07-08T12:37:52.000ZSanner Grouphttps://www.pharmaradar360.com/article/gr23193050-martinella-crush-nail-polish-2-x-4ml-581bc0b5682fd599Pharma Surgeen2026-07-08T12:37:14.000ZΑνάκληση της παρτίδας GR23193050 του καλλυντικού προϊόντος βερνίκι νυχιών MARTINELLA CRUSH NAIL POLISH 2 X 4mlhttps://www.pharmaradar360.com/article/the-next-generation-of-medicine-personalized-preventive-and-powered-by-technolog-603fb4dcf99e51bcPharma Surgeen2026-07-08T12:34:09.000ZThe Next Generation of Medicine: Personalized, Preventive, and Powered by Technologyhttps://www.pharmaradar360.com/article/vaccinex-to-show-new-alzheimer-s-biomarker-data-in-london-0bd546cf4fb588b3Pharma Surgeen2026-07-08T12:32:54.000ZVaccinex to show new Alzheimer’s biomarker data in Londonhttps://www.pharmaradar360.com/article/mdd-class-iia-therakos-cellex-photopheresis-procedural-kit-db63e6281b621836Pharma Surgeen2026-07-08T12:32:37.000ZΑνάκληση παρτίδων του Ιατροτεχνολογικού προϊόντος κατηγορίας MDD Class IIa, THERAKOS CELLEX Photopheresis Procedural Kithttps://www.pharmaradar360.com/article/niagen-bioscience-launches-pharmaceutical-program-for-accelerated-aging-and-rare-6e55ccd26baf48dfPharma Surgeen2026-07-08T12:32:00.000ZNiagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseaseshttps://www.pharmaradar360.com/article/diluted-earnings-per-share-diluted-eps-of-veraxa-biotech-ag-nasdaq-vrxaw-48802ab7526d372cPharma Surgeen2026-07-08T12:27:49.000ZDiluted earnings per share (diluted EPS) of Veraxa Biotech AG – NASDAQ:VRXAWhttps://www.pharmaradar360.com/article/10-year-capital-plan-for-health-and-social-care-bb65eafc8b8dfaabPharma Surgeen2026-07-08T12:27:39.000Z10 Year Capital Plan for Health and Social Carehttps://www.pharmaradar360.com/article/c353cdc674a81d83Pharma Surgeen2026-07-08T12:26:25.000ZΕΝΗΜΕΡΩΣΗ ΣΧΕΤΙΚΑ ΜΕ ΤΗΝ ΜΗ ΝΟΜΙΜΗ ΠΑΡΟΥΣΙΑΣΗ, ΠΡΟΩΘΗΣΗ ΚΑΙ ΧΟΡΗΓΗΣΗ «ΕΝΔΟΦΛΕΒΙΩΝ ΘΕΡΑΠΕΙΩΝ»ΩΣ ΣΥΜΠΛΗΡΩΜΑΤΩΝ ΔΙΑΤΡΟΦΗΣhttps://www.pharmaradar360.com/article/rapid-refill-continuous-injection-system-cefc87c31a61078bPharma Surgeen2026-07-08T12:23:58.000ZΑνάκληση παρτίδων του Ιατροτεχνολογικού προϊόντος Rapid Refill Continuous Injection Systemhttps://www.pharmaradar360.com/article/what-is-the-multi-billion-dollar-uk-us-pharmaceutical-deal-9c4ae2cd090de713Pharma Surgeen2026-07-08T12:10:06.000ZWhat is the Multi Billion Dollar UK-US Pharmaceutical Deal?https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-4-report-data-to-week-3-data-up-to-2e74c55ab5f0ff0cPharma Surgeen2026-07-08T12:08:29.000ZNational Norovirus and Rotavirus Report, week 4 report: data to week 3 (data up to 24 January 2027)https://www.pharmaradar360.com/article/national-norovirus-and-rotavirus-report-week-3-report-data-to-week-2-data-up-to-66b5e36a07bd61ecPharma Surgeen2026-07-08T12:08:03.000ZNational Norovirus and Rotavirus Report, week 3 report: data to week 2 (data up to 17 January 2027)https://www.pharmaradar360.com/article/beperkte-beschikbaarheid-van-azactam-1-g-en-2-g-poeder-voor-oplossing-voor-injec-7eb4a1294de06995Pharma Surgeen2026-07-08T12:06:44.000ZBeperkte beschikbaarheid van Azactam 1 g en 2 g poeder voor oplossing voor injectie/infusie: aanbevelingen voor artsen-specialisten en ziekenhuisapothekershttps://www.pharmaradar360.com/article/aspen-leader-highlights-importance-of-skills-collaboration-and-technology-in-dri-619d32b8294bed7fPharma Surgeen2026-07-08T12:02:23.000ZAspen leader highlights importance of skills, collaboration and technology in driving manufacturing competitivenesshttps://www.pharmaradar360.com/article/two-lots-of-omnitrope-injectable-human-growth-hormone-recalled-due-to-cracked-ca-58e3244b80691557Pharma Surgeen2026-07-08T12:00:00.000ZTwo lots of Omnitrope injectable human growth hormone recalled due to cracked cartridgeshttps://www.pharmaradar360.com/article/allura-xper-fd10-5ed4d41d78a53269Pharma Surgeen2026-07-08T12:00:00.000ZAllura Xper FD10https://www.pharmaradar360.com/article/alice-le-system-sleepware-software-9953d87514222f41Pharma Surgeen2026-07-08T12:00:00.000ZAlice Le System - Sleepware Softwarehttps://www.pharmaradar360.com/article/joincare-pharmaceutical-group-industry-co-ltd-sponsored-gdr-class-a-regs-897f9783c98b672aPharma Surgeen2026-07-08T11:59:55.000ZJoincare Pharmaceutical Group Industry Co., Ltd. Sponsored GDR Class A RegShttps://www.pharmaradar360.com/article/japan-s-tanabe-sells-pharma-factory-to-towa-pharmaceutical-1f7cd75247d1e109Pharma Surgeen2026-07-08T11:59:27.000ZJapan's Tanabe sells Pharma Factory to Towa Pharmaceuticalhttps://www.pharmaradar360.com/article/ananda-pharma-confirms-safety-of-mrx1-cbd-drug-as-clinical-pain-trials-approach-b32fa53b28863f17Pharma Surgeen2026-07-08T11:58:59.000ZAnanda Pharma Confirms Safety of MRX1 CBD Drug, as Clinical Pain Trials Approachhttps://www.pharmaradar360.com/article/pharmaceutical-technology-7c050c9468f47fa7Pharma Surgeen2026-07-08T11:54:26.000ZPharmaceutical Technologyhttps://www.pharmaradar360.com/article/from-semis-to-biotech-a-market-rotation-not-an-ai-reversal-07c1e7869817ee02Pharma Surgeen2026-07-08T11:35:34.000ZFrom Semis to Biotech: A Market Rotation, Not an AI Reversalhttps://www.pharmaradar360.com/article/chemomab-scipher-tie-merger-to-ai-guided-rheumatoid-arthritis-trial-8d5eb3540bc540a3Pharma Surgeen2026-07-08T11:35:00.000ZChemomab, Scipher tie merger to AI-guided rheumatoid arthritis trialhttps://www.pharmaradar360.com/article/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-f-fd6ca6c361aa80a7Pharma Surgeen2026-07-08T11:30:48.000ZImmunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumorshttps://www.pharmaradar360.com/article/aura-biosciences-announces-appointment-of-jeremy-bender-ph-d-m-b-a-to-board-of-d-012fcb51d275aad8Pharma Surgeen2026-07-08T11:23:16.000ZAura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directorshttps://www.pharmaradar360.com/article/price-to-earnings-forward-of-kobayashi-pharmaceutical-co-ltd-tradegate-koy-78b08374a3ffb121Pharma Surgeen2026-07-08T11:20:05.000ZPrice to earnings forward of Kobayashi Pharmaceutical Co., Ltd. – TRADEGATE:KOYhttps://www.pharmaradar360.com/article/minister-mulls-establishing-national-network-to-collect-expired-medicines-preven-698e453a5f92ac63Pharma Surgeen2026-07-08T11:17:00.000ZMinister mulls establishing national network to collect expired medicines, prevent recirculationhttps://www.pharmaradar360.com/article/us-food-and-drug-administration-rejects-petition-to-set-pfas-limits-in-food-04003d1a61a989d6Pharma Surgeen2026-07-08T11:02:00.000ZUS Food and Drug Administration rejects petition to set Pfas limits in foodhttps://www.pharmaradar360.com/article/rovi-y-la-junta-de-castilla-la-mancha-impulsan-un-marco-de-colaboracion-para-mod-12dcb657bf929dd8Pharma Surgeen2026-07-08T11:00:27.000ZROVI y la Junta de Castilla La Mancha impulsan un marco de colaboración para modernizar servicios sanitarios mediante innovación tecnológicahttps://www.pharmaradar360.com/article/letter-to-the-chair-of-the-food-standards-agency-6bc2df2e1d3b54efPharma Surgeen2026-07-08T11:00:01.000ZLetter to the chair of the Food Standards Agencyhttps://www.pharmaradar360.com/article/food-standards-agency-fsa-economic-growth-goals-ef2f7dbf3dbf38abPharma Surgeen2026-07-08T11:00:01.000ZFood Standards Agency (FSA) economic growth goalshttps://www.pharmaradar360.com/article/fsa-mhra-and-nice-economic-growth-goals-0e0f299be89b45f6Pharma Surgeen2026-07-08T11:00:01.000ZFSA, MHRA and NICE economic growth goalshttps://www.pharmaradar360.com/article/national-institute-for-health-and-care-excellence-nice-economic-growth-goals-88099fabb5625953Pharma Surgeen2026-07-08T11:00:00.000ZNational Institute for Health and Care Excellence (NICE) economic growth goalshttps://www.pharmaradar360.com/article/policy-paper-medicines-and-healthcare-products-regulatory-agency-mhra-economic-g-c0ca8208ee7f614bPharma Surgeen2026-07-08T11:00:00.000ZPolicy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goalshttps://www.pharmaradar360.com/article/okyo-pharma-reports-positive-feedback-from-fda-type-d-6d6057e2fc8c1dd1Pharma Surgeen2026-07-08T11:00:00.000ZOKYO Pharma Reports Positive Feedback from FDA Type Dhttps://www.pharmaradar360.com/article/fda-feedback-pushes-okyo-pharma-into-phase-3-eye-pain-study-08287565b0a5ffc4Pharma Surgeen2026-07-08T11:00:00.000ZFDA feedback pushes OKYO Pharma into Phase 3 eye-pain studyhttps://www.pharmaradar360.com/article/keenova-s-xiaflex-met-phase-3-goals-in-foot-disorder-trial-ceb29c14c9129a72Pharma Surgeen2026-07-08T11:00:00.000ZKeenova's XIAFLEX met Phase 3 goals in foot disorder trialhttps://www.pharmaradar360.com/article/former-merck-and-nasa-leaders-bring-strategic-expertise-to-spacemd-amid-rising-d-8d67dfcff2cdddecPharma Surgeen2026-07-08T11:00:00.000ZFormer Merck and NASA Leaders Bring Strategic Expertise to SpaceMD Amid Rising Demand for its In-Space Pharmaceutical Development Capabilitieshttps://www.pharmaradar360.com/article/astrazeneca-secures-ex-china-license-for-sino-biopharmaceutical-s-experimental-c-48f0f0f196a1d95bPharma Surgeen2026-07-08T10:56:01.000ZAstraZeneca secures ex-China license for Sino Biopharmaceutical’s experimental COPD drughttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-is-up-7-4-after-index-migration-to-russell-2000-a-9e0157fbeb64a870Pharma Surgeen2026-07-08T10:35:21.000ZUltragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-rare-is-up-7-4-after-index-migration-to-russell-2000-a-002aac08317669d2Pharma Surgeen2026-07-08T10:35:19.000ZUltragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value Benchmarks - Has The Bull Case Changed?https://www.pharmaradar360.com/article/meningococcal-reference-unit-request-form-ceafb7601bb3e0b8Pharma Surgeen2026-07-08T10:12:02.000ZMeningococcal reference unit request formhttps://www.pharmaradar360.com/article/life-sciences-tools-services-stocks-q1-results-benchmarking-10x-genomics-nasdaq-6afbb3c2806af5eaPharma Surgeen2026-07-08T10:06:43.000ZLife Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)https://www.pharmaradar360.com/article/meningococcal-reference-unit-mru-user-manual-0adcf7a237409564Pharma Surgeen2026-07-08T10:03:36.000ZMeningococcal reference unit (MRU): user manualhttps://www.pharmaradar360.com/article/us-biotech-firm-raises-multi-million-series-b-to-scale-astaxanthin-production-427a35ee79dfb406Pharma Surgeen2026-07-08T09:45:00.000ZUS biotech firm raises multi-million series B to scale astaxanthin productionhttps://www.pharmaradar360.com/article/india-renews-push-for-pharma-market-access-in-china-2372cab3c3b7967bPharma Surgeen2026-07-08T09:45:00.000ZIndia renews push for pharma market access in Chinahttps://www.pharmaradar360.com/article/register-medical-devices-to-place-on-the-market-5d9542deb10b4ffbPharma Surgeen2026-07-08T09:38:38.000ZRegister medical devices to place on the markethttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-timing-pharmaceutical-co-ltd-tpex-6659-f08b02814bf569f2Pharma Surgeen2026-07-08T09:18:49.000ZEnterprise value to EBITDA forward of Timing Pharmaceutical Co. Ltd. – TPEX:6659https://www.pharmaradar360.com/article/new-hospital-programme-annual-report-financial-year-2025-to-2026-c61c57596ef1d3e7Pharma Surgeen2026-07-08T09:13:59.000ZNew Hospital Programme annual report: financial year 2025 to 2026https://www.pharmaradar360.com/article/cover-vaccine-coverage-statistics-data-submission-and-publication-dates-66e32106701ccc1bPharma Surgeen2026-07-08T09:10:31.000ZCOVER vaccine coverage statistics: data submission and publication dateshttps://www.pharmaradar360.com/article/three-biotech-tenants-move-into-former-athenahealth-hq-3760d6c98e422a8cPharma Surgeen2026-07-08T09:00:00.000ZThree biotech tenants move into former athenahealth HQhttps://www.pharmaradar360.com/article/is-biomarin-pharmaceutical-bmrn-still-below-fair-value-after-its-russell-index-a-16918df014fab421Pharma Surgeen2026-07-08T08:38:50.000ZIs BioMarin Pharmaceutical (BMRN) Still Below Fair Value After Its Russell Index Additions?https://www.pharmaradar360.com/article/abl-bio-advances-abl111-to-phase-3-in-first-line-gastric-cancer-paving-the-way-f-2a7eec91771feb0bPharma Surgeen2026-07-08T08:37:16.000ZABL Bio advances ABL111 to Phase 3 in first-line gastric cancer, paving the way for 4-1BB platform licensing-outhttps://www.pharmaradar360.com/article/okyo-pharma-reports-fda-feedback-advances-urcosimod-into-phase-3-trial-for-neuro-0575f076bdb4f668Pharma Surgeen2026-07-08T08:33:00.000ZOKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal painhttps://www.pharmaradar360.com/article/helix-opens-genomic-cohorts-to-astrazeneca-cdae4d4c2710ead3Pharma Surgeen2026-07-08T08:17:40.000ZHelix opens genomic cohorts to AstraZenecahttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-hunan-er-kang-pharmaceutical-co-ltd-class-a-12b48f10dc97a906Pharma Surgeen2026-07-08T08:14:43.000ZEnterprise value to EBIT forward of Hunan Er-Kang Pharmaceutical Co., Ltd. Class A – SZSE:300267https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-kobayashi-pharmaceutical-co-ltd-tse-4967-46d68894aa2f619cPharma Surgeen2026-07-08T08:13:18.000ZEnterprise value to revenue forward of Kobayashi Pharmaceutical Co., Ltd. – TSE:4967https://www.pharmaradar360.com/article/suven-life-sciences-allocates-1-85-crore-shares-at-134-to-raise-248-84-crore-5504a7f6f89a11d2Pharma Surgeen2026-07-08T07:58:52.000ZSuven Life Sciences Allocates 1.85 Crore Shares At ₹134 To Raise ₹248.84 Crorehttps://www.pharmaradar360.com/article/always-one-step-ahead-anne-petit-on-making-medicines-happen-99953b4068537be6Pharma Surgeen2026-07-08T07:57:35.000ZAlways one step ahead: Anne Petit on making medicines happenhttps://www.pharmaradar360.com/article/serum-institute-s-dengue-drug-to-undergo-global-trials-early-next-year-5f97f773d071bc5fPharma Surgeen2026-07-08T07:37:04.000ZSerum Institute’s dengue drug to undergo global trials early next yearhttps://www.pharmaradar360.com/article/ligachem-biosciences-pivots-to-late-stage-adc-2-0-invests-1-trillion-won-chosunb-732ff94c938edf4bPharma Surgeen2026-07-08T07:16:00.000ZLigaChem Biosciences pivots to late-stage ADC 2.0, invests 1 trillion won - CHOSUNBIZhttps://www.pharmaradar360.com/article/fda-suspends-heera-sweets-fssai-licence-638c7e070bd9ecb5Pharma Surgeen2026-07-08T07:13:58.000ZFDA suspends Heera Sweets’ FSSAI licencehttps://www.pharmaradar360.com/article/new-cancer-drug-vepdegestrant-gets-fda-approval-3cca99892162c399Pharma Surgeen2026-07-08T07:07:11.000ZNew Cancer Drug Vepdegestrant Gets FDA Approvalhttps://www.pharmaradar360.com/article/1-2026-0fe160449905d401Pharma Surgeen2026-07-08T06:54:42.000ZΤελικές Προτεινόμενες _ Νέα 1ου Τριμήνου 2026 _ Ανατιμολόγηση προϊόντων αναφοράς λόγω λήξης της προστασίας δεδομένων τουςhttps://www.pharmaradar360.com/article/fda-confirms-single-phase-3-trial-sufficient-for-ath434-nda-in-msa-fa63cdd450a0c869Pharma Surgeen2026-07-08T06:54:09.000ZFDA Confirms Single Phase 3 Trial Sufficient for ATH434 NDA in MSAhttps://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-29-report-data-to-week-28-dat-3eecc552c8c5e93ePharma Surgeen2026-07-08T06:49:38.000ZNational flu and COVID-19 surveillance report, week 29 report: data to week 28 (data up to 12 July 2026)https://www.pharmaradar360.com/article/biotech-double-winners-outperform-the-market-with-fundamental-tailwinds-poised-t-e95e5ff58e42d060Pharma Surgeen2026-07-08T06:42:37.000ZBiotech Double Winners Outperform the Market, With Fundamental Tailwinds Poised to Sustain Momentumhttps://www.pharmaradar360.com/article/takeda-completed-issuance-of-new-shares-and-disposal-of-treasury-shares-under-th-de84d12450044281Pharma Surgeen2026-07-08T06:30:36.000ZTakeda Completed Issuance of New Shares and Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan with Partial Forfeiture of Rights Granted to Allottees | Takeda Pharmaceuticalshttps://www.pharmaradar360.com/article/first-aid-a-new-idea-for-the-biotech-act-73f597158e4db8d7Pharma Surgeen2026-07-08T06:28:31.000ZFIRST AID: A new idea for the Biotech Acthttps://www.pharmaradar360.com/article/s2g-hatch-backed-biotech-raises-millions-expands-corbion-ties-5454207d3e5e09eaPharma Surgeen2026-07-08T06:05:15.000ZS2G, Hatch-backed biotech raises millions, expands Corbion tieshttps://www.pharmaradar360.com/article/kintara-kins-price-prediction-2025-2026-will-it-rise-433afe050dc6e270Pharma Surgeen2026-07-08T06:04:17.000ZKintara (KINS) Price Prediction 2025–2026: Will It Rise?https://www.pharmaradar360.com/article/avacta-appoints-healthcare-executive-patrick-vink-as-deputy-chairman-of-the-boar-658571a1441a8f91Pharma Surgeen2026-07-08T06:03:17.000ZAvacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directorshttps://www.pharmaradar360.com/article/china-s-biotech-boom-ras-targeted-drugs-challenge-us-dominance-3c2b6c6acdf8bdadPharma Surgeen2026-07-08T06:00:12.000ZChina’s biotech boom: RAS-targeted drugs challenge US dominancehttps://www.pharmaradar360.com/article/us-fda-declines-to-approve-unicycive-s-kidney-disease-drug-acbf6fe9a8b3f539Pharma Surgeen2026-07-08T05:59:58.000ZUS FDA declines to approve Unicycive's kidney disease drughttps://www.pharmaradar360.com/article/why-is-sichuan-kelun-biotech-stock-sliding-today-5b87bf8c57895db1Pharma Surgeen2026-07-08T05:55:53.000ZWhy is Sichuan Kelun Biotech stock sliding today?https://www.pharmaradar360.com/article/d-d-pharmatech-earns-milestone-as-partner-advances-fap-pet-imaging-agent-into-ph-933b0ac4d4800d5fPharma Surgeen2026-07-08T05:49:56.000ZD&D Pharmatech earns milestone as partner advances FAP PET imaging agent into phase 2https://www.pharmaradar360.com/article/new-weight-loss-pill-beats-oral-ozempic-in-major-trial-71303654f91f8decPharma Surgeen2026-07-08T05:29:22.000ZNew weight loss pill beats oral Ozempic in major trialhttps://www.pharmaradar360.com/article/d-d-pharmatech-earns-milestone-as-partner-advances-fap-pet-imaging-agent-into-ph-df5f53eb9fd8ca35Pharma Surgeen2026-07-08T05:24:37.000ZD&D Pharmatech earns milestone as partner advances FAP PET imaging agent into phase 2https://www.pharmaradar360.com/article/woojung-bio-changes-name-to-kolmar-biotech-after-joining-kolmar-group-08ffde28665ecfc1Pharma Surgeen2026-07-08T05:17:10.000ZWoojung Bio changes name to Kolmar BioTech after joining Kolmar Grouphttps://www.pharmaradar360.com/article/vktx-vs-bcrx-which-biotech-takeover-favorite-offers-more-upside-after-vertex-s-1-3f511bc74011a51fPharma Surgeen2026-07-08T05:14:31.000ZVKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?https://www.pharmaradar360.com/article/vktx-vs-bcrx-which-biotech-takeover-favorite-offers-more-upside-after-vertex-s-1-9f358803ca3b9132Pharma Surgeen2026-07-08T05:11:00.000ZVKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?https://www.pharmaradar360.com/article/ono-pharmaceutical-tse-4528-could-be-33-undervalued-as-opdivo-and-pipeline-progr-546c5af262a6f57bPharma Surgeen2026-07-08T05:08:14.000ZOno Pharmaceutical (TSE:4528) Could Be 33% Undervalued As Opdivo And Pipeline Progress Buildhttps://www.pharmaradar360.com/article/aribio-nears-phase-3-results-for-oral-alzheimer-s-drug-mason-capital-s-investmen-db513a87f3646f6fPharma Surgeen2026-07-08T04:55:17.000ZAribio Nears Phase 3 Results for Oral Alzheimer’s Drug... Mason Capital’s Investment Performance Becomes Visiblehttps://www.pharmaradar360.com/article/bpc-157-not-fda-approved-the-u-s-food-and-drug-administration-is-moving-toward-a-a63624218fcfc954Pharma Surgeen2026-07-08T04:53:59.000Zbpc 157 not fda approved The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies ⁠to produce more than a dozen injectable peptides that were banned because of ⁠potentially significant safety risks, the New Yorkhttps://www.pharmaradar360.com/article/exposeiq-juryfit-helps-pharmaceutical-litigation-teams-transform-jury-selection-c907d646e69d1cfePharma Surgeen2026-07-08T04:24:13.000ZExposeIQ JuryFit Helps Pharmaceutical Litigation Teams Transform Jury Selection Strategy with Human-Verified Insightshttps://www.pharmaradar360.com/article/geared-power-biotech-ceo-gary-kellstrom-jr-featured-on-going-beyond-the-deal-pod-2c9efd48b0a5a176Pharma Surgeen2026-07-08T04:18:00.000ZGeared Power BioTech CEO, Gary Kellstrom, Jr. Featured on 'Going Beyond the Deal' Podcast with J. Michael Fischer, Jr.https://www.pharmaradar360.com/article/hc-questions-fda-push-to-invoke-mcoca-in-food-safety-cases-across-maha-fcb9e5bd41c90abcPharma Surgeen2026-07-08T03:43:08.000ZHC questions FDA push to invoke MCOCA in food safety cases across Mahahttps://www.pharmaradar360.com/article/medipost-inc-treats-first-u-s-participant-in-phase-iii-trial-of-umbilical-cord-s-b06511214f9a733cPharma Surgeen2026-07-08T02:43:00.000ZMEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis - PR Newswire APAChttps://www.pharmaradar360.com/article/three-pharmaceutical-stocks-to-consider-buying-to-profit-from-a-weight-loss-tren-b5783866e0fae922Pharma Surgeen2026-07-08T02:40:11.000ZThree Pharmaceutical Stocks to Consider Buying to Profit from a Weight-Loss Trendhttps://www.pharmaradar360.com/article/pangea-pharmaceuticals-advances-its-next-phase-of-growth-with-an-expanding-comme-6e83c8b200dcb713Pharma Surgeen2026-07-08T01:40:21.000ZPangea Pharmaceuticals Advances Its Next Phase of Growth With an Expanding Commercial Portfoliohttps://www.pharmaradar360.com/article/medipost-doses-first-patient-in-u-s-phase-3-trial-for-knee-osteoarthritis-cell-t-b60b100516ced2b9Pharma Surgeen2026-07-08T01:17:00.000ZMedipost Doses First Patient in U.S. Phase 3 Trial for Knee Osteoarthritis Cell Therapy 'Cartistem'https://www.pharmaradar360.com/article/medipost-s-cartistem-begins-u-s-phase-3-doses-first-patient-5570110fb340b198Pharma Surgeen2026-07-08T00:38:25.000ZMedipost's Cartistem Begins U.S. Phase 3, Doses First Patienthttps://www.pharmaradar360.com/article/the-fda-must-reinstate-safety-restrictions-for-abortion-drug-82473f95bf17f7e6Pharma Surgeen2026-07-08T00:01:56.000ZThe FDA Must Reinstate Safety Restrictions for Abortion Drughttps://www.pharmaradar360.com/article/moderna-filed-form-8-k-738819d8b969f9c5Pharma Surgeen2026-07-08T00:00:00.000ZModerna filed Form 8-Khttps://www.pharmaradar360.com/article/novel-life-saving-liver-procedure-recommended-potentially-enabling-hundreds-more-fd16c74af776d6dcPharma Surgeen2026-07-08T00:00:00.000ZNovel life-saving liver procedure recommended, potentially enabling hundreds more transplantshttps://www.pharmaradar360.com/article/view-all-news-articles-c59e11b18e2ad94dPharma Surgeen2026-07-08T00:00:00.000ZView all news articles